title: Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study.
abstract: BACKGROUND
  Numerous studies examining the prevalence and natural history of dyspepsia in the general population have been conducted. However, few have reported the effect of quality of life on the development of dyspepsia. A 10-year longitudinal follow-up study examining the effect of quality of life on subsequent dyspepsia was performed.
  
  
  METHODS
  Individuals originally enrolled in a population-screening programme for Helicobacter pylori were contacted through a validated postal dyspepsia questionnaire. Baseline demographic data, quality of life at original study entry, and dyspepsia and irritable bowel syndrome (IBS) symptom data were already on file. Consent to examine primary-care records was sought, and data regarding non-steroidal anti-inflammatory drugs (NSAID) and aspirin use were obtained from these.
  
  
  RESULTS
  Of 8407 individuals originally involved, 3912 (46.5%) provided symptom data at baseline and 10-year follow-up. Of 2550 (65%) individuals asymptomatic at study entry, 717 (28%) developed new-onset dyspepsia at 10 years, an incidence of 2.8% per year. After multivariate logistic regression, lower quality of life at study entry (OR 2.63; 99% CI 1.86 to 3.71), higher body mass index (OR per unit 1.05; 99% CI 1.02 to 1.08), presence of IBS at study entry (OR 3.1; 99% CI 1.51 to 6.37) and use of NSAIDs and/or aspirin (OR 1.32; 99% CI 0.99 to 1.75) were significant risk factors for new-onset dyspepsia.
  
  
  CONCLUSIONS
  The incidence of new-onset dyspepsia was almost 3% per year. Low quality of life at baseline exerted a strong effect on the likelihood of developing dyspepsia at 10 years.
authors.affiliation: Department of Academic Medicine, Clinical Sciences Building, St James's University Hospital, Leeds, UK. alexf12399@yahoo.com
authors.forename: Alexander C
authors.initials: AC
authors.lastname: Ford
authors.forename: David
authors.initials: D
authors.lastname: Forman
authors.forename: Alastair G
authors.initials: AG
authors.lastname: Bailey
authors.forename: Anthony T R
authors.initials: AT
authors.lastname: Axon
authors.forename: Paul
authors.initials: P
authors.lastname: Moayyedi
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001241:Aspirin / Q000009:adverse effects; D015992:Body Mass Index; D004415:Dyspepsia / Q000453:epidemiology / Q000209:etiology*; D004739:England / Q000453:epidemiology; D004812:Epidemiologic Methods; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000150:complications; D008019:Life Style; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012923:Social Class
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin